# OnCo record nct07653685 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07653685/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07653685", "NCT07653685" ;
  schema:name "A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan"@en ;
  schema:description "A phase 1/2 trial of capecitabine and bevacizumab in colorectal cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07653685/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07653685> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/>, <https://onco.cc/cancers/her2-amplified-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> .